The ICER Impact.

New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million

Read More

Engaged with over 300 patient groups and patient reps

In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model

Read More


Policy Papers.

Easy access to our ongoing policy papers

Barriers to Fair Access

First-ever scorecard of several key appropriate access criteria reveals variation across largest payers but high concordance for clinical eligibility criteria, step therapy, and provider restrictions; lower concordance found for formulary tiering criteria.

Read More

Unsupported Price Increases

Out of 10 identified drugs that had substantial 2020 price increases net of rebates on top of already high current spending, seven were not supported by new clinical evidence; net price increases on these seven drugs cost Americans an additional $1.67 billion in annual drug spend, of which nearly $1.4 billion was due to a single drug alone: Humira.

Read More

Evaluating Reforms to Orphan Drug Development, Pricing, and Coverage

This White Paper presents an analysis of the potential risks and benefits of reforms seeking to strengthen evidence on orphan drugs and to ensure that adequate incentives for orphan drug development are coupled to a more sustainable long-term trajectory for orphan drug pricing.

Read More



Group of Patients

Learn more about how the patient perspective influences ICER’s work, and learn how you can be involved.

ICER podcast logo

Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.

Cost-Effectiveness, the evLYG,

the QALY, and Fair Drug Pricing.

Learn More.